8-K: LAVA Therapeutics Delays XOMA Acquisition Vote

LAVA Therapeutics has postponed its Extraordinary General Meeting to early November 2025 to further discuss transaction terms with XOMA Royalty Corporation.

Summary

• LAVA Therapeutics N.V. canceled its Extraordinary General Meeting (EGM) scheduled for September 30, 2025.
• The EGM was intended to consider and approve matters related to XOMA Royalty Corporation's offer to purchase all LAVA common shares.
• The cancellation is to allow for continued discussions with XOMA regarding transaction terms, including LAVA's estimated cash forecast and the consideration payable to shareholders.
• Both LAVA and XOMA Royalty Corporation remain committed to completing the transaction.
• The EGM is expected to be reconvened by early November 2025, with the specific date, record date, and location to be announced later.
• Shareholders who previously cast votes for the original EGM will need to re-cast them for the reconvened meeting.

Sentiment

Score: 4

Explanation: While both parties remain committed to the transaction, the cancellation and delay of the EGM, coupled with the need for further discussions on financial terms and the explicit risk of less favorable terms for shareholders, introduce uncertainty and suggest a less straightforward path than initially presented. The commitment to close is a positive, but the underlying reasons for the delay are concerning.

Positives

• Both LAVA Therapeutics and XOMA Royalty Corporation remain committed to completing the acquisition transaction.
• The acquisition is still anticipated to close in the fourth quarter of 2025.

Negatives

• The Extraordinary General Meeting (EGM) scheduled for September 30, 2025, was canceled, delaying the shareholder vote.
• The delay is due to ongoing discussions with XOMA concerning transaction terms, including LAVA's estimated cash forecast and the consideration payable to shareholders, indicating potential unresolved issues.
• Shareholders who previously cast votes will need to re-cast them for the reconvened EGM, adding an administrative burden.
• There is an explicit risk that the terms of the transaction may be revised to be less favorable to LAVA's shareholders.

Risks

• The transaction may not be completed in a timely manner, or at all, which could adversely affect LAVA's business and the price of its common shares.
• The terms of the transaction may be revised to be less favorable to LAVA's shareholders.
• Delay or failure of the terms of the transaction to be revised or of the offer conditions to be satisfied (or waived), including insufficient common shares tendered, may impact the amount payable to shareholders.
• The possibility that competing offers will be made.
• Significant costs associated with the transaction.
• Any shareholder or other litigation in connection with the transaction may result in significant costs of defense, indemnification, and liability.
• Activities related to the CVR agreement may not result in any value to LAVA's shareholders.
• Prior to the completion of the transaction, LAVA's or XOMA's business may experience significant disruptions due to transaction-related uncertainty.
• Disruption from the transactions may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, or business partners.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the purchase agreement.
• Potential adverse effects on LAVA's business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities (e.g., Russian invasion of Ukraine and the conflict in the Middle East).

Future Outlook

The company expects to reconvene the Extraordinary General Meeting by early November 2025 and anticipates closing the acquisition by XOMA Royalty Corporation in the fourth quarter of 2025. Discussions are ongoing to finalize transaction terms, including LAVA's cash forecast and shareholder consideration.

Management Comments

• "We are committed to closing this transaction and look forward to working collaboratively with the LAVA team to further define LAVAs cash forecast in an effort to close this transaction in an expeditious manner." Owen Hughes, CEO of XOMA Royalty.

Industry Context

This announcement reflects a common occurrence in M&A transactions, where due diligence and finalization of terms can lead to adjustments in timelines or conditions. For biopharmaceutical companies like LAVA, which often rely on partnerships and acquisitions for value realization, the successful completion of such transactions is critical. The delay, while not ideal, is framed within the context of ensuring accurate financial assessments for the deal.

Corporate Governance

Legal Proceedings

• Risk of shareholder or other litigation in connection with the transaction, potentially resulting in significant costs of defense, indemnification, and liability.

Stakeholder Impact

• Shareholders: Will experience a delay in the transaction approval process, need to re-cast votes, and face the risk of less favorable transaction terms. Potential for disruption to share price.
• Employees, Manufacturers, Suppliers, Vendors, Business Partners: May experience significant disruptions due to transaction-related uncertainty, making it more difficult to establish or maintain relationships.

Next Steps

• LAVA Therapeutics will continue discussions with XOMA Royalty Corporation regarding transaction terms, cash forecast, and shareholder consideration.
• LAVA Therapeutics will determine and announce the new meeting date, record date, and location for the reconvened EGM.
• LAVA Therapeutics plans to send a revised proxy statement and proxy card to shareholders for the reconvened EGM.
• Shareholders will need to re-cast their votes for the reconvened EGM.
• The acquisition is anticipated to close in the fourth quarter of 2025.

Key Dates

Recommendation

The delay in the EGM and the ongoing discussions about transaction terms, including the potential for less favorable terms for shareholders, introduce significant uncertainty. While both parties remain committed to the acquisition, the specifics of the revised terms are unknown. Investors should hold to await clarity on the finalized terms and the outcome of the reconvened EGM before making further decisions. The explicit risk of less favorable terms warrants caution.

Keywords

LAVA Therapeutics, LVTX, XOMA Royalty Corporation, acquisition, merger, tender offer, EGM, shareholder meeting, biopharmaceutical, Gammabody, JNJ-89853413, PF-08046052, NASDAQ